Medicis Pharmaceutical Corp  

(Public, NYSE:MRX)   Watch this stock  
Find more results for MRX
0.0000
0.0000 (0.00%)
- Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.67
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin 0.52% 14.83%
Operating margin 8.75% 25.43%
EBITD margin - 29.89%
Return on average assets 0.20% 7.66%
Return on average equity 0.44% 12.48%
Employees 646 -
CDP Score - -

Address

700 Route 202/206 North
BRIDGEWATER, NJ 08807
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).